Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1944 1
1945 10
1946 16
1947 13
1948 17
1949 18
1950 42
1951 42
1952 57
1953 46
1954 56
1955 35
1956 32
1957 28
1958 47
1959 28
1960 30
1961 24
1962 29
1963 26
1964 34
1965 40
1966 28
1967 24
1968 26
1969 29
1970 28
1971 30
1972 42
1973 34
1974 35
1975 30
1976 38
1977 30
1978 38
1979 45
1980 49
1981 46
1982 37
1983 49
1984 37
1985 51
1986 53
1987 43
1988 67
1989 55
1990 65
1991 61
1992 69
1993 82
1994 88
1995 120
1996 95
1997 79
1998 101
1999 128
2000 137
2001 131
2002 128
2003 118
2004 103
2005 119
2006 159
2007 138
2008 161
2009 177
2010 181
2011 197
2012 242
2013 240
2014 265
2015 286
2016 312
2017 417
2018 485
2019 693
2020 1188
2021 1643
2022 1772
2023 1830
2024 1834
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,141 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E; ESMO Guidelines Committee. Electronic address: [email protected]. Cervantes A, et al. Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25. Ann Oncol. 2023. PMID: 36307056 Free article. No abstract available.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. Nat Med. 2023. PMID: 37845511 Free PMC article. Clinical Trial.
Epidemiology of acne and rosacea: A worldwide global study.
Saurat JH, Halioua B, Baissac C, Cullell NP, Ben Hayoun Y, Aroman MS, Taieb C, Skayem C. Saurat JH, et al. J Am Acad Dermatol. 2024 May;90(5):1016-1018. doi: 10.1016/j.jaad.2023.12.038. Epub 2024 Jan 4. J Am Acad Dermatol. 2024. PMID: 38184278 Free article. No abstract available.
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, di Pietro A, Cantey-Kiser J, Edwards M, Ascierto PA. Dummer R, et al. J Clin Oncol. 2022 Dec 20;40(36):4178-4188. doi: 10.1200/JCO.21.02659. Epub 2022 Jul 21. J Clin Oncol. 2022. PMID: 35862871 Free PMC article. Clinical Trial.
Endemic Kaposi's Sarcoma.
Zeinaty PE, Lebbé C, Delyon J. Zeinaty PE, et al. Cancers (Basel). 2023 Jan 31;15(3):872. doi: 10.3390/cancers15030872. Cancers (Basel). 2023. PMID: 36765830 Free PMC article. Review.
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Menzer C, et al. J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3. J Clin Oncol. 2019. PMID: 31580757 Free PMC article.
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. Schadendorf D, et al. Eur J Cancer. 2024 Jun;204:114073. doi: 10.1016/j.ejca.2024.114073. Epub 2024 Apr 24. Eur J Cancer. 2024. PMID: 38723373 Free article. Clinical Trial.
Donitriptan (Pierre Fabre).
Dukat M. Dukat M. Curr Opin Investig Drugs. 2001 Mar;2(3):415-8. Curr Opin Investig Drugs. 2001. PMID: 11575714
Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. ...
Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. ...
Evolution of HER2 Targeting in Metastatic Breast Cancer.
Bartsch R, Balic M. Bartsch R, et al. Breast Care (Basel). 2022 Dec;17(6):521-523. doi: 10.1159/000528002. Epub 2022 Nov 10. Breast Care (Basel). 2022. PMID: 36590142 Free PMC article. No abstract available.
In memoriam: Dr. Francesc Abel Fabre, S.J.
Terribas N. Terribas N. J Med Philos. 2012 Oct;37(5):503. doi: 10.1093/jmp/jhs036. Epub 2012 Nov 4. J Med Philos. 2012. PMID: 23129780 No abstract available.
14,141 results
You have reached the last available page of results. Please see the User Guide for more information.